A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Recruiting in Palo Alto (17 mi)

+15 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.

Research Team

Eligibility Criteria

Inclusion Criteria

Cohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria

Histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution

Patient planning to receive systemic treatment

See 7 more

Treatment Details

Interventions

Blood Draw (Biomarker Test)
Cyst Fluid (Biomarker Test)
Tumor Tissue Collection (Biomarker Test)

Participant Groups

4Treatment groups

Experimental Treatment

Group I: Locally Advanced or Metastatic Pancreatic Cancer CohortExperimental Treatment2 Interventions

For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.

Group II: Healthy ControlExperimental Treatment1 Intervention

For normal controls, blood specimens will be drawn once at study baseline.

Group III: Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst CtrlExperimental Treatment3 Interventions

For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.

Group IV: Acute Benign Pancreatic Pathology Control CohortExperimental Treatment2 Interventions

For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter